Altered balance between proteolysis and antiproteolysis in oncohematologic diseases

  • O. E. Shaul’ska "Dnipropetrovsk Medical Academy of the Health Ministry of Ukraine" SE
  • L. M. Diachenko "Dnipropetrovsk Medical Academy of the Health Ministry of Ukraine" SE
  • T. P. Nikolayenko-Kamyshova "City Multi-Field Clinical Hospital 4 RSA Dnipropetrovsk" SI
  • A. I. Shevtsova "Dnipropetrovsk Medical Academy of the Health Ministry of Ukraine" SE
Keywords: degradation of proteins, acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, anthracycline antibiotics

Abstract

Destruction of malignant cell clones and search for markers of the effectiveness of chemotherapy in patients with hematologic malignancies is an urgent direction of research. The purpose of this paper was to study plasma of patients with various forms of blood tumor, the activity of trypsin-like enzymes, matrix metalloproteinases MMP2 and MMP9, content of α1-proteinase inhibitor and α2-macroglobulin before and after the cytotoxic therapy by anthracycline antibiotics, doxorubicin and daunorubicin. It was established that concentration of inhibitors and activity of trypsin-like enzymes increased in patients with acute myeloid leukemia and multiple myeloma against the backdrop of multidirectional changes of proMMP9. Activity of the latter enzyme was reduced to 0,03±0,01 rel. u. in acute myeloid leukemia, and after chemotherapy it increased 7 times. Reducing level of inhibitors and increasing activity of MMP9 were found in chronic lymphocytic leukemia. The presence of the correlation between the α2-macroglobulin and gelatinase activity in the treatment indicates that the inhibitor is an important mechanism for storing of gelatinоlytic potential. Balance between proteolysis and antiproteolysis depends on the type of proliferating cells and the course of the disease. Indicators of tissue destruction may be an additional criterion for monitoring the stage of blood tumors and efficacy of treatment.

References

Butylin, A.A., Panteleev, M.A., Ataullahanov, F.A., 2007. Prostranstvennaja dinamika svertyvanija krovi [The spatial dynamics of blood coagulation]. Rossijskij Himicheskij Zhurnal 51(1), 45–50 (in Russian).

Gajdamaka, N.V., Parovichnikova, E.N., Zavalishina, L.J., Savchenko, V.G., Frank, G.A., 2009. Jekspressija matriksnyh metalloproteinaz i ih ingibitorov v kostnom mozge u bol'nyh ostrymi lejkozami [Expression of matrix metalloproteinases and their inhibitors in the bone marrow of patients with acute leukemia]. Gematologija i Transfuziologija 54(2), 3–10 (in Russian).

Glanc, S., 1999. Mediko-biologicheskaja statistika [Biomedical statistics]. Praktika, Moscow (in Russian).

Hidalgo, M., Eckhardt, S.G., 2001. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl. Cancer Inst. 93(3), 178–193. >> doi: 10.1093/jnci/93.3.178

Hultberg, B., Sjögren, U., 1980. Diagnostic significance of lysosomal enzymes in different types of leukemias. Acta Med. Scand. 207, 105–110. >> doi: 10.1111/j.0954-6820.1980.tb09685.x

Jarovaja, G.A., 2005. Bioregulirujushhie funkcii i patogeneticheskaja rol' proteoliza. Fiziologicheskaja rol' i biohimicheskie mehanizmy – reakcij ogranichennogo proteoliza [Bioregulatory functions and pathogenetic role of proteolysis. The physiological role and biochemical mechanisms – reactions limited proteolysis]. Laboratornaja Medicina 7, 81–90 (in Russian).

Kessenbrock, K., Plaks, V., Werb, Z., 2010. Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell 14(1), 52–67. >> doi: 10.1016/j.cell.2010.03.015

Mecham, R.P., 2012. Overview of extracellular matrix. Curr. Protoc. Cell Biol. 10, Unit 10.1. – doi: 10.1002/0471143030.cb1001s57.

Pamyrskyj, Y.E., 2009. Analiz stepeni strukturnoj i funkcional'noj odnotipnosti polivalentnogo ingibitora proteaz, soderzhashhegosja v podzheludochnoj zheleze zhivotnyh, i soevogo ingibitora tripsina [Analysis of the degree of structural and functional uniformity of the polyvalent protease inhibitor contained in the pancreas of animals, and soybean trypsin inhibitor]. Dis. … kand. biol. nauk. Blagoveshhensk (in Russian).

Parfenova, E.V., Tkachuk, V.A., Men'shikov, M.J., Korshunov, V.A., Plexanova, O.S., Solomatyna, M.A., Bashtrykov, P.P., Berk, B.S., 2006. Aktivatory plazminogena i matriksnye me-talloproteinazy pri jeksperimental'nom remodelirovanii arterij [Plasminogen activators and matrix metalloproteinases in experimental arterial remodeling]. Bjulleten' Jeksperimental'noj Biologii i Mediciny 9, 273–276 (in Russian).

Rozario, T., DeSimone, D.W., 2010. The extracellular matrix in development and morphogenesis: A dynamic view. Dev. Biol. 341(1), 126–140. >> doi: 10.1016/j.ydbio.2009.10.026

Shevcova, A.I., Gordijenko, J.A., Shaul's'ka, O.E., Skoromna, A.S., 2013. Pat. 83196 UA, MPK G 01 N33/49 Sposib vyznachennja zhelatynaz u plazmi krovi [Method for determination of plasma gelatinases]; Zajavnyk ta patentovlasnyk DZ «Dnipropetrovska medychna akademija MOZ Ukrai'ny» – zajavl. 26.03.13; opubl. 27.08.13, Bjul. 16 (in Ukrainian).

Shevcova, A.I., Gordijenko, J.A., Shaul's'ka, O.E., Djachenko, L.M, 2014. Zminy proteazno-antyproteaznogo balansu pry lejkemii [Changes of protease-antyprotease balance for leukemia]. Ukrai'ns'kyj Biohimichnyj Zhurnal 86(5, dodatok 2), 35–36 (in Ukrainian).

Veremeenko, K.N., Goloborod'ko, O.P., Kizim, A.I., 1988. Proteoliz v norme i pri patologii [Proteolysis in normal and pathological conditions]. Zdorovja, Kiev (in Russian).

Veremeenko, K.N., Kizim, A.I., Dosenko, V.E., 2000. α2-Makro-globulin: Struktura, fiziologicheskaja rol' i klinicheskoe znachenie [α2-Macroglobulin: Structure, physiological role and clinical significance]. Laboratornaja Diagnostika 2, 3–9 (in Russian).

Wiedow, O., Meyer-Hoffert, U., 2005. Neutrophil serine proteases: Potential key regulators of cell signalling during inflammation. J. Intern. Med. 257(4), 319–328. >> doi: 10.1111/j.1365-2796.2005.01476.x

Published
2015-03-27
How to Cite
Shaul’ska, O. E., Diachenko, L. M., Nikolayenko-Kamyshova, T. P., & Shevtsova, A. I. (2015). Altered balance between proteolysis and antiproteolysis in oncohematologic diseases. Regulatory Mechanisms in Biosystems, 6(1), 63-67. https://doi.org/10.15421/021512